CN118252895A - Traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema and preparation method thereof Download PDFInfo
- Publication number
- CN118252895A CN118252895A CN202410359628.4A CN202410359628A CN118252895A CN 118252895 A CN118252895 A CN 118252895A CN 202410359628 A CN202410359628 A CN 202410359628A CN 118252895 A CN118252895 A CN 118252895A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- emphysema
- chronic bronchitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 206010014561 Emphysema Diseases 0.000 title claims abstract description 48
- 206010006451 bronchitis Diseases 0.000 title claims abstract description 41
- 206010006458 Bronchitis chronic Diseases 0.000 title claims abstract description 40
- 208000007451 chronic bronchitis Diseases 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 210000004072 lung Anatomy 0.000 claims abstract description 71
- 210000003734 kidney Anatomy 0.000 claims abstract description 29
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 16
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 16
- 235000008434 ginseng Nutrition 0.000 claims abstract description 16
- 241001522129 Pinellia Species 0.000 claims abstract description 14
- 244000197580 Poria cocos Species 0.000 claims abstract description 14
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 235000006533 astragalus Nutrition 0.000 claims abstract description 12
- 241000405414 Rehmannia Species 0.000 claims abstract description 10
- 241001061264 Astragalus Species 0.000 claims abstract description 8
- 210000004233 talus Anatomy 0.000 claims abstract description 8
- 235000021028 berry Nutrition 0.000 claims abstract description 6
- 244000131316 Panax pseudoginseng Species 0.000 claims description 27
- 230000007812 deficiency Effects 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 14
- 241000132446 Inula Species 0.000 claims description 13
- 241000605372 Fritillaria Species 0.000 claims description 12
- 241000123069 Ocyurus chrysurus Species 0.000 claims description 12
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 12
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims description 10
- 244000078912 Trichosanthes cucumerina Species 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 240000006079 Schisandra chinensis Species 0.000 claims description 9
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 241000045403 Astragalus propinquus Species 0.000 claims description 4
- 240000000249 Morus alba Species 0.000 claims description 4
- 235000008708 Morus alba Nutrition 0.000 claims description 4
- 241000405911 Rehmannia glutinosa Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 18
- 208000026435 phlegm Diseases 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 208000006673 asthma Diseases 0.000 abstract description 11
- 210000000952 spleen Anatomy 0.000 abstract description 11
- 210000002784 stomach Anatomy 0.000 abstract description 10
- 238000010926 purge Methods 0.000 abstract description 6
- 208000004880 Polyuria Diseases 0.000 abstract description 5
- 230000035619 diuresis Effects 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 2
- 241000208340 Araliaceae Species 0.000 abstract 1
- 208000000059 Dyspnea Diseases 0.000 description 21
- 206010013975 Dyspnoeas Diseases 0.000 description 21
- 206010011224 Cough Diseases 0.000 description 19
- 241000700159 Rattus Species 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000013220 shortness of breath Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 210000005240 left ventricle Anatomy 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 8
- 206010036790 Productive cough Diseases 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 102000016387 Pancreatic elastase Human genes 0.000 description 5
- 108010067372 Pancreatic elastase Proteins 0.000 description 5
- 230000004872 arterial blood pressure Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 206010008479 Chest Pain Diseases 0.000 description 4
- 206010008469 Chest discomfort Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000001147 pulmonary artery Anatomy 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 210000005241 right ventricle Anatomy 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 210000000596 ventricular septum Anatomy 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 241000233788 Arecaceae Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010013954 Dysphoria Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229940107666 astragalus root Drugs 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009325 pulmonary function Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema, which is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 20-30 parts of ginseng, 15-25 parts of astragalus, 20-30 parts of prepared rhizome of rehmannia, 18-22 parts of shizandra berry, 15-25 parts of pinellia tuber, 20-30 parts of poria cocos and the like, has the effects of nourishing liver and spleen and kidney, reducing stomach qi, purging lung and relieving asthma, inducing diuresis and detumescence, activating blood and dissolving stasis, regulating qi and resolving phlegm, and is used for treating chronic bronchitis complicated with emphysema. The invention also discloses a preparation method and application thereof.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema and a preparation method thereof.
Background
Chronic bronchitis is a chronic nonspecific inflammation of the trachea, bronchus mucosa and surrounding tissues, is clinically characterized by cough, excessive phlegm, shortness of breath and other symptoms and repeated chronic processes, and can be secondary to chronic obstructive emphysema and pulmonary heart disease in severe cases. The disease is caused by a number of factors, including chronic specific inflammation of the trachea, bronchi mucosa and surrounding tissues. The sudden increase of mucus secretion and the proliferation of bronchioles are common pathological phenomena of chronic bronchitis. Patients with chronic bronchitis usually continue to expectorate and cough for more than 3 months, even with asthma, and most patients develop relatively mild clinical symptoms in early stages of the disease. Chronic bronchitis is relatively light in spring onset, but is relatively serious in winter, and patients with serious advanced disease can have clinical symptoms for a long time. Chronic bronchitis recurs, resulting in disability in most patients and a compromised mental well being. Chronic bronchitis and emphysema often occur simultaneously.
The pathogenic cause of emphysema is that the disease is developed by gradual aggravation due to lung deficiency, susceptibility to exogenous pathogenic factors and accumulation of turbid phlegm, so that the occurrence and development of emphysema have two factors, namely internal and external factors. Lesions first in the lung, then affect the spleen, kidneys, later stages and heart. The lung governs qi and governs respiration, and opens into the nose and out of the exterior of the body. Therefore, when exogenous pathogenic factors invade from the mouth and nose and skin, they first attack the lung, cause pathogenic factors to stagnate in the lung, and the adverse airway, the abnormal ascending and descending of qi will cause dyspnea, cough and expectoration. The lung is the top-hat of five zang organs leading to the heart, the lung is the delicate heart, and is not resistant to invasion of pathogenic factors, and the invasion of pathogenic qi of other zang organs can cause the lung to lose dispersing and descending, the lung is full of qi, blocks the airway, and dyspnea is caused by dyspnea. The internal and external pathogenic factors are combined, the disease is not healed after a long time, the disease is repeatedly generated, and finally lung deficiency is caused. Then, lung deficiency is marked by qi failure, short qi and increased dyspnea. The lung deficiency is long-term and the kidney causes the lung not to be in charge of qi, the kidney does not receive qi, the dyspnea is serious, the inhalation is difficult, and the shortness of breath is difficult to continue. Because of the deficiency of lung qi, it is not possible to assist the heart in moving blood vessels. The heart yang is root on the fire of the gate, the kidney deficiency and the heart qi and the heart yang are deficient, and the blood vessels cannot be stimulated to run, so that the stagnation of blood is caused, the dark purple face, lips, tongue and nail bed occur, dyspnea is aggravated, chest fullness and lying down are frequent, lung and kidney deficiency is serious, malignant circulation is formed, and the disease is deeper.
The traditional Chinese medicine has good effect on treating respiratory diseases, and particularly shows the unique advantages of the traditional Chinese medicine in respiratory disease prevention and treatment. Traditional chinese medicine has irreplaceable, even increasingly important roles of western medicine in the respiratory department, both in the past, present and in the future. Has unique advantages in respiratory department and prevention and cure of respiratory system diseases.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema and a preparation method thereof. The invention has the effects of nourishing liver, spleen and kidney, reducing stomach qi, purging lung, relieving asthma, inducing diuresis to alleviate edema, promoting blood circulation, removing blood stasis, regulating qi and resolving phlegm, and achieves the aim of treating diseases on the basis of conditioning the physique of patients; the traditional Chinese medicine composition is clinically used for treating chronic bronchitis complicated with emphysema, and has quick curative effect and no toxic or side effect.
The technical scheme adopted for solving the technical problems is as follows:
A traditional Chinese medicine composition for treating chronic bronchitis combined emphysema is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 20-30 parts of ginseng, 15-25 parts of astragalus membranaceus, 20-30 parts of rehmannia glutinosa, 18-22 parts of schisandra chinensis, 15-25 parts of pinellia ternate, 20-30 parts of poria cocos, 15-25 parts of inula flower, 15-25 parts of calcined concha arcae, 20-30 parts of snakegourd fruit, 15-25 parts of fritillaria, 18-22 parts of semen lepidii, 15-25 parts of cortex mori radicis, 10-20 parts of pseudo-ginseng, 20-30 parts of madder, 18-22 parts of fructus aurantii and 20-30 parts of dried orange peel.
The traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 25 parts of ginseng, 20 parts of astragalus, 25 parts of prepared rhizome of rehmannia, 20 parts of shizandra berry, 20 parts of pinellia tuber, 25 parts of poria cocos, 20 parts of inula flower, 20 parts of calcined concha arcae, 25 parts of snakegourd fruit, 20 parts of fritillaria, 20 parts of semen lepidii, 20 parts of white mulberry root-bark, 15 parts of pseudo-ginseng, 25 parts of madder, 20 parts of fructus aurantii and 25 parts of dried orange peel.
The traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 20 parts of ginseng, 25 parts of astragalus, 20 parts of prepared rhizome of rehmannia, 22 parts of schisandra chinensis, 15 parts of pinellia ternate, 30 parts of poria cocos, 15 parts of inula flower, 25 parts of calcined concha arcae, 20 parts of snakegourd fruit, 25 parts of fritillaria, 18 parts of semen lepidii, 25 parts of cortex mori radicis, 10 parts of pseudo-ginseng, 30 parts of madder, 18 parts of fructus aurantii and 30 parts of dried orange peel.
The traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 30 parts of ginseng, 15 parts of astragalus membranaceus, 30 parts of rehmannia glutinosa, 18 parts of schisandra chinensis, 25 parts of pinellia ternate, 20 parts of poria cocos, 25 parts of inula flower, 15 parts of calcined concha arcae, 30 parts of fructus trichosanthis, 15 parts of fritillaria, 22 parts of semen lepidii, 15 parts of cortex mori radicis, 20 parts of pseudo-ginseng, 20 parts of madder, 22 parts of fructus aurantii and 20 parts of pericarpium citri reticulatae.
The preparation method of the traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema comprises the following specific steps:
(1) Pulverizing the traditional Chinese medicine raw materials in parts by weight, sieving, and uniformly mixing;
(2) Decocting with water twice, each time the water content is 9-11 times of the weight of the Chinese medicinal materials, extracting for 80-120 min, filtering to remove residues, collecting the medicinal liquid, concentrating under reduced pressure to obtain fluid extract, and drying to obtain dry extract;
(3) Adding auxiliary materials into the dry extract obtained in the step (2), uniformly mixing, and preparing a preparation.
The preparation method of the traditional Chinese medicine composition for treating chronic bronchitis combined emphysema comprises the steps of concentrating under reduced pressure at 60-80 ℃ and drying at 60-80 ℃.
The traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema is prepared from one of granules, tablets and capsules.
The application of the traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema in preparing the medicine for treating chronic bronchitis complicated with emphysema is provided.
The application of the traditional Chinese medicine composition for treating the chronic bronchitis combined emphysema in preparing the medicine for treating the chronic bronchitis combined emphysema is characterized in that the chronic bronchitis combined emphysema belongs to deficiency of both lung and kidney.
The chronic bronchitis complicated with emphysema is characterized by the traditional Chinese medicine name of 'lung distention', which is caused by cough, asthma and the like, and is characterized by the symptoms of long-term non-healing, deficiency of lung, spleen and kidney, unfavorable airway obstruction, fullness in chest, cough and asthma with upper qi, frequent and frequent use, or excessive phlegm production accompanied by dark complexion, cyanosis of lips and tongue, edema of facial limbs, long-term lingering course and difficult healing. Deficiency is a common symptom, and is divided into deficiency of both lung and kidney and deficiency of both spleen and kidney, which are common in both lung and kidney. Symptoms: shortness of breath, low voice, dyspnea with dynamic movement, dark complexion or edema of the face and eyes. Pale tongue with white coating, deep and weak pulse, cough with little sputum, chest fullness and dysphoria, feverish sensation in the palms and soles, shortness of breath, dry mouth, desire to drink, red tongue with clean coating, deep and thready pulse. The lung governs qi, the kidneys receive qi, the lung is the main part of qi, the kidneys are the root of qi, the lung deficiency clears and loses the essence, the kidney deficiency does not receive qi, the clear qi is difficult to enter, the oil gas is difficult to exit, so that the chest is full and dyspnea is caused, and the qi is short when the lung is motivated; the lung qi is deficient, so that the voice is low; the dark complexion is the condition of qi deficiency and blood stasis; edema of face and eyes, qi deficiency and water retention; pale tongue coating and deep and weak pulse are also the symptoms of qi deficiency of the lung and kidney. Yin deficiency of lung and kidney, heat is generated internally, so it is manifested as feverish sensation in palms and soles, dry mouth and dysphoria; if lung yin is deficient and descending is not authorized, chest fullness and cough are not enough, and phlegm is less and difficult; the symptoms of red, clear coating and deep and thready pulse are lung and kidney yin deficiency. The invention treats by the following treatment methods, namely, tonifying qi and lung, nourishing kidney and astringing lung; secondly, because phlegm is generated by dampness, spleen transportation and strengthening can lead the dampness to be self-transformed, and the phlegm is unobstructed by a qi-dissipating machine when the dampness is removed, and spleen transportation and strengthening can be carried out, a spleen-tonifying method is adopted; thirdly, the main disease is in the lung, and cough and malaise are usually caused by incoordination of lung qi, failure of dispersing and descending and internal generation of phlegm-dampness in early stage, and the cough and malaise are not healed after long time, and other viscera are often affected, and the symptoms of excessive wood deficiency are that the excessive phlegm is turbid (heat) and the lung is obstructed, and the deficiency is that the lung, spleen and kidney are all deficient. Adopts the treatment principle of eliminating pathogenic factors, detoxifying, resolving phlegm, purging lung, relieving asthma, inducing diuresis and relieving edema; fourth, lung qi descending is descending and stomach qi descending is harmonizing, and "descending" refers to the common characteristic of lung qi and stomach qi. The stomach and lung are adjacent, the stomach and lung are in the same way as the respiratory gate, and any pathogenic qi can affect the descending function of the lung, which leads to the upward adverse flow of lung qi and cough, so the "Su Wen-Ke Lun" summarizes the pathogenesis of cough as to the theory of the lung. The method of reducing stomach qi and resisting gastric acid is adopted, and attention is paid to the qi of protecting lung and defensive qi and the qi of spleen and stomach so as to enhance the defending function of respiratory tract and gastrointestinal mucosa. Primordial Zhu Danxi "Danxi Xin Fa-cough" indicates that lung distention and phlegm stasis are related to each other: the patient should nourish blood to flow qi, reduce fire and sooth liver to clear phlegm because of the cough caused by lung distention or insomnia, which is caused by blood stasis. Fifthly, the drugs for activating blood and dissolving stasis are adopted to search and remove phlegm and blood stasis in the lung so as to clear deficiency of lung collaterals and smooth qi and blood. Sixth, qi root in kidney and lung. Cough and asthma are chronic, and the patient is not ill in menstrual period, and lung qi is injured; the lung and kidney are deficient. The lung does not govern qi but stagnates, the kidney does not receive qi but reverses, while ascending and descending, the qi of the lung and kidney cannot be communicated mutually, so that clear qi is difficult to enter, turbid qi is difficult to exit, stagnates in the chest, and is blocked in the lung due to plastic obstruction. For example, sui Dynasty nest element formula, "the pathogenesis of various diseases: the lung is mainly qi, and when pathogenic factors are accumulated in the lung, the lung will be distended, the lung will be in disorder, and when adverse qi is present, the airway will be blocked, so that the qi will be dyspnea. For this reason, the recipe of qi-regulating and phlegm-resolving treatment is adopted.
The invention adopts ginseng and astragalus root to replenish qi and tonify lung, prepared rhizome of rehmannia and shizandra berry to nourish kidney and astringe lung, pinellia tuber and poria cocos to invigorate spleen and eliminate dampness, inula flower and calcined concha arcae to reduce stomach qi, and the ginseng and the astragalus root and the prepared rhizome of Chinese magnoliavine are all monarch drugs; fructus Trichosanthis, bulbus Fritillariae Cirrhosae with effects of removing toxic substances, eliminating phlegm, purging lung, semen Lepidii, cortex Mori with effects of purging lung, relieving asthma, inducing diuresis and relieving edema, and can be used as ministerial drug; 37. radix Rubiae has effects of promoting blood circulation and removing blood stasis, and is used as adjuvant drug; fructus Aurantii and pericarpium Citri Tangerinae with qi regulating and phlegm eliminating effects are used as guiding drugs, and the whole formula of the Chinese medicinal materials comprises Ginseng radix, radix astragali, radix rehmanniae Preparata, fructus Schisandrae chinensis, rhizoma Pinelliae, poria, inulae flos, concha arcae, fructus Trichosanthis, bulbus Fritillariae Cirrhosae, semen Lepidii, cortex Mori, notoginseng radix, radix Rubiae, fructus Aurantii, and pericarpium Citri Tangerinae, has effects of nourishing liver and spleen kidney, reducing stomach qi, purging lung, relieving asthma, inducing diuresis to alleviate edema, promoting blood circulation for removing blood stasis, regulating qi-flowing and eliminating phlegm, and can be used for treating chronic bronchitis complicated with emphysema.
Detailed Description
The application is further described below in conjunction with the detailed description. It is to be understood that these examples are illustrative of the present application and are not intended to limit the scope of the present application. Further, it is understood that various changes and modifications of the present application may be made by those skilled in the art after reading the description of the present application, and that such equivalents are intended to fall within the scope of the application as defined in the appended claims.
Example 1: the preparation method comprises the following specific steps of taking 250g of ginseng, 200g of astragalus, 250g of prepared rhizome of rehmannia, 200g of shizandra berry, 200g of pinellia tuber, 250g of poria cocos, 200g of inula flower, 200g of calcined concha arcae, 250g of snakegourd fruit, 200g of fritillaria, 200g of semen lepidii, 200g of white mulberry root-bark, 150g of pseudo-ginseng, 250g of madder, 200g of fructus aurantii and 250g of dried orange peel:
(1) Pulverizing the traditional Chinese medicine raw materials in parts by weight, sieving, and uniformly mixing;
(2) Decocting with water twice, each time with water 10 times of the weight of the Chinese medicinal materials, extracting for 100min, filtering to remove residue, collecting medicinal liquid, concentrating under reduced pressure at 70deg.C to obtain fluid extract, and drying at 70deg.C to obtain dry extract;
(3) Adding starch into the dry extract obtained in the step (2), uniformly mixing, and preparing into granules.
Example 2: 200g of ginseng, 250g of astragalus, 200g of prepared rhizome of rehmannia, 220g of schisandra chinensis, 150g of pinellia tuber, 300g of poria cocos, 150g of inula flower, 250g of calcined concha arcae, 200g of snakegourd fruit, 250g of fritillaria, 180g of semen lepidii, 250g of cortex mori radicis, 100g of pseudo-ginseng, 300g of madder, 180g of fructus aurantii and 300g of dried orange peel are taken, and the preparation method comprises the following specific steps:
(1) Pulverizing the traditional Chinese medicine raw materials in parts by weight, sieving, and uniformly mixing;
(2) Decocting with water twice, each time with water amount 9 times of the weight of the Chinese medicinal materials, extracting for 120min, filtering to remove residue, collecting medicinal liquid, concentrating under reduced pressure at 60deg.C to obtain fluid extract, and drying at 80deg.C to obtain dry extract;
(3) Adding dextrin into the dry extract obtained in the step (2), uniformly mixing, and preparing into tablets.
Example 3: 300g of ginseng, 150g of astragalus, 300g of prepared rhizome of rehmannia, 180g of schisandra chinensis, 250g of pinellia ternate, 200g of poria cocos, 250g of inula flower, 150g of calcined concha arcae, 300g of snakegourd fruit, 150g of fritillaria, 220g of semen lepidii, 150g of cortex mori radicis, 200g of pseudo-ginseng, 200g of madder, 220g of fructus aurantii and 200g of dried orange peel are taken, and the preparation method comprises the following specific steps:
(1) Pulverizing the traditional Chinese medicine raw materials in parts by weight, sieving, and uniformly mixing;
(2) Decocting with water twice, each time with water 11 times the weight of the Chinese medicinal materials, extracting for 80min, filtering to remove residue, collecting medicinal liquid, concentrating under reduced pressure at 80deg.C to obtain fluid extract, and drying at 60deg.C to obtain dry extract;
(3) Adding microcrystalline cellulose into the dry extract obtained in the step (2), uniformly mixing, and making into capsule.
Example 4: pharmacodynamics research on emphysema of the invention
Experimental principle: previous studies suggest that a protease/antiprotease system imbalance in pulmonary tissues of emphysema is one of its major factors, with elastase playing an extremely important role in the development and progression of emphysema. The pharmacodynamics research of the invention on emphysema is carried out by adopting an elastase-induced rat experimental emphysema model.
Experimental animals and reagents: SD rats, male, weighing 250-280g, supplied by the university of Yangzhou laboratory animal center. Reagent: elastase (Porcine PANCREATIC ELASTASE PPE) manufactured by Changzhou Qianzhong biopharmaceutical Co., ltd., lot: 73100303;1mg = 17.5 active units (μ), dissolved in sterile physiological saline and formulated for the desired concentration application. Instrument: RM-6000 type multi-guide physiological recorder, japanese photoelectric product.
And (3) molding experiment: after the experimental rats were anesthetized with diethyl ether, the rats were fixed in a position facing upward, the median incision of the neck was about 1.5cm, and after the trachea was separated, an elastase sterile physiological saline solution was injected from the trachea with a 5# needle, at a dose of 100u/100g, and a volume of 0.2 ml/rat. The rats were then allowed to stand upright and gently swirled to allow uniform contact with lung tissue, maintaining the respiratory tract unobstructed. The skin was then sutured and penicillin was instilled locally to prevent infection. Rats survived 24 hours after surgery were randomly divided into a model group, a normal control group and an example 1 group. The normal control group and the model group were orally administered with physiological saline at a dose of 20ml/kg, and the example 1 group was orally administered with the granules prepared in example 1 at a dose of 20g crude drug/kg. The administration was performed by lavage once daily for 30 consecutive days.
Observation index 1: determination of pulmonary arterial pressure (PPA): 24 hours after the last administration, rats were anesthetized with pentobarbital sodium 40mg/kg ip, the left sternum was opened, artificial positive pressure artificial respiration was performed with a small animal respirator, and pulmonary artery pressure was recorded with a RM-6000 type multi-guide physiological recorder after pulmonary artery intubation.
Observation index 2: right ventricle to left ventricle plus ventricular septum ratio (RV/lv+s): after pulmonary artery pressure is measured, the rat is sacrificed by bleeding, heart is dissected, residual blood is flushed, large blood vessels and auricles are cut off, the right ventricle is cut off from the edge of the junction of the right ventricle and the ventricular septum, the left ventricle and the ventricular septum are respectively weighed, and the condition of the right ventricle hypertrophy is observed by taking the percentage of the left ventricle (RV) divided by the Left Ventricle (LV) +ventricular septum (S) as an index.
The experimental results are shown in Table 1.
TABLE 1 Effect of the invention on laboratory emphysema PPA and RV/LV+S in rats
| Grouping | PPA(mmHg.x±s) | RV/LV+S(％.x±s) |
| Normal control group | 21.45±2.76 | 29.13±4.97 |
| Model group | 28.37±2.14## | 37.75±3.24## |
| Example 1 group | 22.74±2.47* | 30.76±4.04* |
Note # # P <0.01; * P <0.05; # is compared to the normal group; * Comparing with the model group;
From the results in table 1, it can be seen that: the pulmonary artery pressure of the rat with experimental emphysema after modeling is obviously increased, the RV/LV+S ratio is increased, and compared with a normal control group, the difference has significance (P < 0.05), which indicates that modeling is successful. The continuous administration of the granules in example 1 group for 30 days resulted in a decrease in PPA and a decrease in RV/LV+S ratio in rats. The invention can obviously reduce the pulmonary arterial pressure rise of the rat experimental emphysema model, reduce the ratio of RV/LV+S, and also has obvious improvement effect on the rat experimental emphysema model.
Example 5: clinical trials
Case selection: 100 cases of chronic bronchitis with deficiency of both the lung and the kidney, which are treated in the hospitals in Taizhou city, are collected from month 1 in 2022 to month 10 in 2023 and combined with emphysema, and are divided into two groups of 50 cases.
Inclusion criteria: the symptoms of recurrent cough, expectoration and wheezing exist, and the annual attack time lasts for more than 3 months and more than 3 years. The lung function examination suggests an increase in residual gas/lung capacity > 35%, with the first second exhale/forced lung capacity being less than 60%. The Chinese medicine is diagnosed as deficiency of lung and kidney, and symptoms are short breath, low voice, dyspnea due to movement, dark complexion or edema of face and eyes. Pale tongue with white coating, deep and weak pulse, cough with little sputum, chest fullness and dysphoria, feverish sensation in the palms and soles, shortness of breath, dry mouth, desire to drink, red tongue with clean coating, deep and thready pulse.
Exclusion criteria: (1) acute onset phase of chronic obstructive emphysema; (2) Combining bronchial asthma, bronchitis and respiratory malignant tumor; (3) there are peptic ulcers; (4) gestational women; (5) mental disorder; (6) poor therapeutic compliance.
The treatment method comprises the following steps: the control group was treated with the conventional therapy, namely, tiotropium bromide powder inhalant (lot 20210308, boringer John pharmaceutical Co., germany) 18ug, 1 inhalation per day. Example 1 the granule prepared in example 1 was taken with the daily dosage of 25g of ginseng, 20g of astragalus root, 25g of prepared rehmannia root, 20g of shizandra berry, 20g of pinellia tuber, 25g of tuckahoe, 20g of inula flower, 20g of calcined concha arcae, 25g of snakegourd fruit, 20g of fritillaria, 20g of semen lepidii, 20g of white mulberry root-bark, 15g of pseudo-ginseng, 25g of madder root, 20g of bitter orange and 25g of dried orange peel, and the granule was taken three times daily.
And (3) observing the indexes: (1) Pulmonary function indicators, including FEV1/FVC, FVC, PEF, were detected using a pulmonary function instrument (model AS-507, japan Meinai Co.); (2) CAT score, traditional Chinese medicine syndrome score and 6min walking distance, wherein the CAT score comprises 7 items of sleeping, going out, expectoration, activities, climbing stairs, chest distress and cough, and is classified into 3 grades according to severity, the higher the classification is, the more serious the classification is, and the highest score is 5 grades; the Chinese medicine symptoms include cough and expectoration (2 minutes, occasional attacks; 4 minutes, recurrent attacks; 6 minutes, cough and expectoration continuously exist and are difficult to relieve), chest distress and asthma (2 minutes, occasional chest distress and shortness of breath can be relieved by self; 4 minutes, chest distress and shortness of breath frequently occur; 6 minutes, continuously exist), shortness of breath (1 minute, slight shortness of breath; 2 minutes, recurrent attacks of shortness of breath can be relieved temporarily; 3 minutes, shortness of breath continuously exists, dynamic attacks), soreness of waist and knees and spontaneous perspiration (1 minute, light in degree, less than 3 days in 1 week of attack, 2 minutes, 3-6 days in 1 week of attack, 3 minutes in each day).
Experimental results: see tables 2 and 3.
Table 2 pulmonary function index comparison (x±s, n=50)
Note that: # P < 0.05 compared with the prior treatment of the same group; △ P < 0.05 compared to control after treatment.
TABLE 3CAT score, traditional Chinese medical Condition score, 6min walking distance comparison
Note that: # P < 0.05 compared with the prior treatment of the same group; △ P < 0.05 compared to control after treatment.
Conclusion of experiment: as can be seen from the results in tables 2 and 3, after the treatment of the control group and the example 1 group, the FEV1/FVC, FVC, PEF of the group is increased (P is smaller than 0.05), the example 1 group is more obvious (P is smaller than 0.05), after the treatment, the CAT score and the traditional Chinese medicine syndrome score of the group 2 are reduced (P is smaller than 0.05), the walking distance of 6min is prolonged (P is smaller than 0.05), and the example 1 group is more obvious (P is smaller than 0.05), so that the invention has good treatment effect on the lung-kidney deficiency type chronic bronchitis and emphysema patients.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (9)
1. The traditional Chinese medicine composition for treating chronic bronchitis combined emphysema is characterized by being prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 20-30 parts of ginseng, 15-25 parts of astragalus membranaceus, 20-30 parts of rehmannia glutinosa, 18-22 parts of schisandra chinensis, 15-25 parts of pinellia ternate, 20-30 parts of poria cocos, 15-25 parts of inula flower, 15-25 parts of calcined concha arcae, 20-30 parts of snakegourd fruit, 15-25 parts of fritillaria, 18-22 parts of semen lepidii, 15-25 parts of cortex mori radicis, 10-20 parts of pseudo-ginseng, 20-30 parts of madder, 18-22 parts of fructus aurantii and 20-30 parts of dried orange peel.
2. The traditional Chinese medicine composition for treating chronic bronchitis complicated by emphysema according to claim 1, wherein the traditional Chinese medicine composition is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 25 parts of ginseng, 20 parts of astragalus, 25 parts of prepared rhizome of rehmannia, 20 parts of shizandra berry, 20 parts of pinellia tuber, 25 parts of poria cocos, 20 parts of inula flower, 20 parts of calcined concha arcae, 25 parts of snakegourd fruit, 20 parts of fritillaria, 20 parts of semen lepidii, 20 parts of white mulberry root-bark, 15 parts of pseudo-ginseng, 25 parts of madder, 20 parts of fructus aurantii and 25 parts of dried orange peel.
3. The traditional Chinese medicine composition for treating chronic bronchitis complicated by emphysema according to claim 1, wherein the traditional Chinese medicine composition is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 20 parts of ginseng, 25 parts of astragalus, 20 parts of prepared rhizome of rehmannia, 22 parts of schisandra chinensis, 15 parts of pinellia ternate, 30 parts of poria cocos, 15 parts of inula flower, 25 parts of calcined concha arcae, 20 parts of snakegourd fruit, 25 parts of fritillaria, 18 parts of semen lepidii, 25 parts of cortex mori radicis, 10 parts of pseudo-ginseng, 30 parts of madder, 18 parts of fructus aurantii and 30 parts of dried orange peel.
4. The traditional Chinese medicine composition for treating chronic bronchitis complicated by emphysema according to claim 1, wherein the traditional Chinese medicine composition is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 30 parts of ginseng, 15 parts of astragalus membranaceus, 30 parts of rehmannia glutinosa, 18 parts of schisandra chinensis, 25 parts of pinellia ternate, 20 parts of poria cocos, 25 parts of inula flower, 15 parts of calcined concha arcae, 30 parts of fructus trichosanthis, 15 parts of fritillaria, 22 parts of semen lepidii, 15 parts of cortex mori radicis, 20 parts of pseudo-ginseng, 20 parts of madder, 22 parts of fructus aurantii and 20 parts of pericarpium citri reticulatae.
5. The traditional Chinese medicine composition for treating chronic bronchitis complicated by emphysema according to claim 1, wherein the preparation method comprises the following specific steps:
(1) Pulverizing the traditional Chinese medicine raw materials in parts by weight, sieving, and uniformly mixing;
(2) Decocting with water twice, each time the water content is 9-11 times of the weight of the Chinese medicinal materials, extracting for 80-120 min, filtering to remove residues, collecting the medicinal liquid, concentrating under reduced pressure to obtain fluid extract, and drying to obtain dry extract;
(3) Adding auxiliary materials into the dry extract obtained in the step (2), uniformly mixing, and preparing a preparation.
6. The traditional Chinese medicine composition for treating chronic bronchitis complicated by emphysema according to claim 5, wherein the temperature of reduced pressure concentration in the preparation method is 60-80 ℃, and the temperature of drying is 60-80 ℃.
7. The traditional Chinese medicine composition for treating chronic bronchitis complicated by emphysema according to claim 5, wherein the preparation is one of granules, tablets and capsules.
8. The use of a Chinese medicinal composition for treating chronic bronchitis complicated by emphysema according to claim 1 in preparing a medicament for treating chronic bronchitis complicated by emphysema.
9. The use of a Chinese medicinal composition for treating chronic bronchitis complicated with emphysema according to claim 1, wherein the chronic bronchitis complicated with emphysema belongs to deficiency of both lung and kidney.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410359628.4A CN118252895A (en) | 2024-03-27 | 2024-03-27 | Traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410359628.4A CN118252895A (en) | 2024-03-27 | 2024-03-27 | Traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118252895A true CN118252895A (en) | 2024-06-28 |
Family
ID=91606343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410359628.4A Pending CN118252895A (en) | 2024-03-27 | 2024-03-27 | Traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118252895A (en) |
-
2024
- 2024-03-27 CN CN202410359628.4A patent/CN118252895A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100408067C (en) | Chinese medicines for stomach pain due to Qi stagnation and its preparing method | |
| CN104013681B (en) | A kind of pharmaceutical composition for the treatment of kidney stone | |
| US20080317879A1 (en) | Herb Composition for Asthma Maintenance Therapy and Manufacturing Method Thereof | |
| CN102764371B (en) | Traditional Chinese medicine compound prescription for relieving radiotherapy side reactions and preparation method and application thereof | |
| CN110237174A (en) | A kind of eliminating dampness Chinese medicine composition and preparation method thereof for treating cold cough | |
| CN106361993A (en) | Medicinal composition for preventing and treating gastric mucosal lesion and preparation method of medicinal composition | |
| CN111529597A (en) | Traditional Chinese medicine composition for gout and/or hyperuricemia | |
| CN111481638A (en) | Traditional Chinese medicine enema preparation for treating ulcerative colitis and preparation method thereof | |
| CN102188689A (en) | Compound combination medicament for treating COPD, preparation method and application thereof | |
| CN114712478B (en) | Traditional Chinese medicine composition for treating intestinal diseases, preparation and preparation method thereof | |
| CN118252895A (en) | Traditional Chinese medicine composition for treating chronic bronchitis complicated with emphysema and preparation method thereof | |
| CN108815448B (en) | Traditional Chinese medicine granules for treating chronic colitis | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN111419894A (en) | Pharmaceutical composition for reducing uric acid and preparation method thereof | |
| CN117018132B (en) | Traditional Chinese medicine for treating cough variant asthma | |
| CN116492420B (en) | Composition for treating chronic obstructive pulmonary disease in stable phase and preparation method and application thereof | |
| CN105999174A (en) | Traditional Chinese medicine for treating diabetes and preparation method thereof | |
| CN105288157A (en) | Traditional Chinese medicine composition with effects of freeing lung and relieving asthma, preparation method and application thereof | |
| CN105055703A (en) | Anti-allergic traditional Chinese medicine composition and preparation method thereof | |
| CN105640792B (en) | Dihydromyricetin is in beauty except the application in spot product | |
| CN111759872A (en) | Medicine for treating hypertension and preparation method thereof | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases | |
| CN113855770A (en) | Traditional Chinese medicine composition for treating reflux esophagitis and preparation method thereof | |
| CN103735857B (en) | The application in preparation treatment pharyngitis medicine of the Dendrobium officinale fruit extract | |
| CN104189288A (en) | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination |